Loading
A phase 2 trial of Tisotumab vedotin, Pembrolizumab, Carboplatin and Cisplatin in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma and head and neck squamous cell carcinoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors is a phase 2 interventional study registered as NCT03485209 by Seagen, a wholly owned subsidiary of Pfizer, with 350 participants enrolled, started 2018-06-25 and due to reach its primary completion in 2026-03-20. Interventions recorded: tisotumab vedotin, pembrolizumab, carboplatin and cisplatin.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Cisplatin, Carboplatin, Antibody-drug conjugate (ADC), Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Head and neck squamous cell carcinoma, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.